<!DOCTYPE html>
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<title>Thrombin Inhibitors | Clinical Hematology</title>
<meta name="author" content="Brett M. Rice">
<meta name="description" content="Overview of Direct Thrombin Inhibitors (DTIs) Definition: Direct thrombin inhibitors (DTIs) are a class of anticoagulant medications that directly bind to and inhibit the activity of thrombin...">
<meta name="generator" content="bookdown 0.42 with bs4_book()">
<meta property="og:title" content="Thrombin Inhibitors | Clinical Hematology">
<meta property="og:type" content="book">
<meta property="og:description" content="Overview of Direct Thrombin Inhibitors (DTIs) Definition: Direct thrombin inhibitors (DTIs) are a class of anticoagulant medications that directly bind to and inhibit the activity of thrombin...">
<meta name="twitter:card" content="summary">
<meta name="twitter:title" content="Thrombin Inhibitors | Clinical Hematology">
<meta name="twitter:description" content="Overview of Direct Thrombin Inhibitors (DTIs) Definition: Direct thrombin inhibitors (DTIs) are a class of anticoagulant medications that directly bind to and inhibit the activity of thrombin...">
<!-- JS --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://kit.fontawesome.com/6ecbd6c532.js" crossorigin="anonymous"></script><script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="libs/bootstrap-4.6.0/bootstrap.min.css" rel="stylesheet">
<script src="libs/bootstrap-4.6.0/bootstrap.bundle.min.js"></script><script src="libs/bs3compat-0.9.0/transition.js"></script><script src="libs/bs3compat-0.9.0/tabs.js"></script><script src="libs/bs3compat-0.9.0/bs3compat.js"></script><link href="libs/bs4_book-1.0.0/bs4_book.css" rel="stylesheet">
<script src="libs/bs4_book-1.0.0/bs4_book.js"></script><!-- Google tag (gtag.js) --><script async src="https://www.googletagmanager.com/gtag/js?id=G-JERRQQFPF4"></script><script>
      window.dataLayer = window.dataLayer || [];
      function gtag(){dataLayer.push(arguments);}
      gtag('js', new Date());

      gtag('config', 'G-JERRQQFPF4');
    </script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- CSS --><style type="text/css">
    
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  </style>
<link rel="stylesheet" href="style.css">
</head>
<body data-spy="scroll" data-target="#toc">

<div class="container-fluid">
<div class="row">
  <header class="col-sm-12 col-lg-3 sidebar sidebar-book"><a class="sr-only sr-only-focusable" href="#content">Skip to main content</a>

    <div class="d-flex align-items-start justify-content-between">
      <h1>
        <a href="index.html" title="">Clinical Hematology</a>
      </h1>
      <button class="btn btn-outline-primary d-lg-none ml-2 mt-1" type="button" data-toggle="collapse" data-target="#main-nav" aria-expanded="true" aria-controls="main-nav"><i class="fas fa-bars"></i><span class="sr-only">Show table of contents</span></button>
    </div>

    <div id="main-nav" class="collapse-lg">
      <form role="search">
        <input id="search" class="form-control" type="search" placeholder="Search" aria-label="Search">
</form>

      <nav aria-label="Table of contents"><h2>Table of contents</h2>
        <ul class="book-toc list-unstyled">
<li><a class="" href="index.html">About</a></li>
<li class="book-part">Erythrocytes</li>
<li><a class="" href="rbc-production.html">RBC Production</a></li>
<li><a class="" href="rbc-function.html">RBC Function</a></li>
<li><a class="" href="rbc-destruction.html">RBC Destruction</a></li>
<li><a class="" href="anemais.html">Anemais</a></li>
<li><a class="" href="microcytic.html">Microcytic</a></li>
<li><a class="" href="iron-deficiency.html">Iron Deficiency</a></li>
<li><a class="" href="chronic-disease.html">Chronic Disease</a></li>
<li><a class="" href="thalassemias.html">Thalassemias</a></li>
<li><a class="" href="sideroblastic.html">Sideroblastic</a></li>
<li><a class="" href="porphyria.html">Porphyria</a></li>
<li><a class="" href="normocytic.html">Normocytic</a></li>
<li><a class="" href="hereditary-hemolytic.html">Hereditary Hemolytic</a></li>
<li><a class="" href="acquired-hemolytic.html">Acquired Hemolytic</a></li>
<li><a class="" href="hypoproliferative.html">Hypoproliferative</a></li>
<li><a class="" href="acute-hemorrhage.html">Acute Hemorrhage</a></li>
<li><a class="" href="macrocytic.html">Macrocytic</a></li>
<li><a class="" href="megaloblastic.html">Megaloblastic</a></li>
<li><a class="" href="nonmegaloblastic.html">Nonmegaloblastic</a></li>
<li><a class="" href="hemoglobinopathies.html">Hemoglobinopathies</a></li>
<li><a class="" href="erythrocytosis.html">Erythrocytosis</a></li>
<li class="book-part">Leukocytes</li>
<li><a class="" href="wbc-production.html">WBC Production</a></li>
<li><a class="" href="wbc-function.html">WBC Function</a></li>
<li><a class="" href="wbc-destruction.html">WBC Destruction</a></li>
<li><a class="" href="benign-disorders.html">Benign Disorders</a></li>
<li><a class="" href="myeloid.html">Myeloid</a></li>
<li><a class="" href="lymphoid.html">Lymphoid</a></li>
<li><a class="" href="myeloid-neoplasia.html">Myeloid Neoplasia</a></li>
<li><a class="" href="aml.html">AML</a></li>
<li><a class="" href="myelodysplastic.html">Myelodysplastic</a></li>
<li><a class="" href="myeloproliferative.html">Myeloproliferative</a></li>
<li><a class="" href="lymphoid-neoplasia.html">Lymphoid Neoplasia</a></li>
<li><a class="" href="acute-lymphoid.html">Acute Lymphoid</a></li>
<li><a class="" href="chronic-b-cell.html">Chronic B-Cell</a></li>
<li><a class="" href="chronic-t-cell.html">Chronic T-Cell</a></li>
<li><a class="" href="plasma-cell.html">Plasma Cell</a></li>
<li class="book-part">Platelets</li>
<li><a class="" href="plt-production.html">PLT Production</a></li>
<li><a class="" href="plt-function.html">PLT Function</a></li>
<li><a class="" href="plt-destruction.html">PLT Destruction</a></li>
<li><a class="" href="quantitative.html">Quantitative</a></li>
<li><a class="" href="thrombocytopenia-1.html">Thrombocytopenia</a></li>
<li><a class="" href="destruction.html">Destruction</a></li>
<li><a class="" href="production.html">Production</a></li>
<li><a class="" href="pseudo.html">Pseudo</a></li>
<li><a class="" href="thrombocytosis.html">Thrombocytosis</a></li>
<li><a class="" href="qualitative.html">Qualitative</a></li>
<li><a class="" href="von-willebrand.html">von Willebrand</a></li>
<li><a class="" href="bernard-soulier.html">Bernard-Soulier</a></li>
<li><a class="" href="glanzmann.html">Glanzmann</a></li>
<li class="book-part">Laboratory</li>
<li><a class="" href="cell-counts.html">Cell Counts</a></li>
<li><a class="" href="manual.html">Manual</a></li>
<li><a class="" href="automated.html">Automated</a></li>
<li><a class="" href="retics.html">Retics</a></li>
<li><a class="" href="differentials.html">Differentials</a></li>
<li><a class="" href="morphologies.html">Morphologies</a></li>
<li><a class="" href="hemoglobin.html">Hemoglobin</a></li>
<li><a class="" href="quantitative-1.html">Quantitative</a></li>
<li><a class="" href="qualitative-1.html">Qualitative</a></li>
<li><a class="" href="electrophoresis.html">Electrophoresis</a></li>
<li><a class="" href="hplc.html">HPLC</a></li>
<li><a class="" href="sickle-solubility.html">Sickle Solubility</a></li>
<li><a class="" href="hematocrit.html">Hematocrit</a></li>
<li><a class="" href="indices.html">Indices</a></li>
<li><a class="" href="hemolysis.html">Hemolysis</a></li>
<li><a class="" href="special-stains.html">Special Stains</a></li>
<li><a class="" href="other-studies.html">Other Studies</a></li>
<li><a class="" href="esr.html">ESR</a></li>
<li><a class="" href="g6pd.html">G6PD</a></li>
<li><a class="" href="heinz-body.html">Heinz Body</a></li>
<li><a class="" href="flow-cytometry.html">Flow Cytometry</a></li>
<li><a class="" href="leukemia.html">Leukemia</a></li>
<li><a class="" href="lymphoma.html">Lymphoma</a></li>
<li><a class="" href="lymphocyte-subsets.html">Lymphocyte Subsets</a></li>
<li><a class="" href="pnh.html">PNH</a></li>
<li><a class="" href="molecularcytogenetic.html">Molecular/Cytogenetic</a></li>
<li><a class="" href="recurring-abnormalities.html">Recurring Abnormalities</a></li>
<li><a class="" href="bcrabl1.html">BCR/ABL1</a></li>
<li><a class="" href="jak2.html">JAK2</a></li>
<li class="book-part">Hemostasis</li>
<li><a class="" href="coagulation-pathways.html">Coagulation Pathways</a></li>
<li><a class="" href="fibrinolytic-pathways.html">Fibrinolytic Pathways</a></li>
<li><a class="" href="vascular-system.html">Vascular System</a></li>
<li><a class="" href="disorders.html">Disorders</a></li>
<li><a class="" href="factor-deficiencies.html">Factor Deficiencies</a></li>
<li><a class="" href="hereditary.html">Hereditary</a></li>
<li><a class="" href="acquired.html">Acquired</a></li>
<li><a class="" href="inhibitors.html">Inhibitors</a></li>
<li><a class="" href="fibrinolytic.html">Fibrinolytic</a></li>
<li><a class="" href="thrombophilia.html">Thrombophilia</a></li>
<li><a class="" href="dic.html">DIC</a></li>
<li><a class="" href="laboratory.html">Laboratory</a></li>
<li><a class="" href="ptinr.html">PT/INR</a></li>
<li><a class="" href="aptt.html">APTT</a></li>
<li><a class="" href="fibrinogen.html">Fibrinogen</a></li>
<li><a class="" href="d-dimer.html">D-dimer</a></li>
<li><a class="" href="thrombin-time.html">Thrombin Time</a></li>
<li><a class="" href="mixing-studies-1.html">Mixing Studies</a></li>
<li><a class="" href="factor-assays.html">Factor Assays</a></li>
<li><a class="" href="inhibitor-assays.html">Inhibitor Assays</a></li>
<li><a class="" href="von-willebrand-assays.html">von Willebrand Assays</a></li>
<li><a class="" href="platelet-function.html">Platelet Function</a></li>
<li><a class="" href="platelet-aggregation.html">Platelet Aggregation</a></li>
<li><a class="" href="thromboelastography.html">Thromboelastography</a></li>
<li><a class="" href="hypercoagulability.html">Hypercoagulability</a></li>
<li><a class="" href="assays.html">Assays</a></li>
<li><a class="" href="antiphospholipids.html">Antiphospholipids</a></li>
<li><a class="" href="protein-c.html">Protein C</a></li>
<li><a class="" href="protein-s.html">Protein S</a></li>
<li><a class="" href="molecular.html">Molecular</a></li>
<li><a class="" href="fv-leiden.html">FV Leiden</a></li>
<li><a class="" href="pt-20210.html">PT 20210</a></li>
<li><a class="" href="anti-xa.html">Anti-Xa</a></li>
<li><a class="active" href="thrombin-inhibitors.html">Thrombin Inhibitors</a></li>
<li><a class="" href="heparin-neutralization.html">Heparin Neutralization</a></li>
</ul>

        <div class="book-extra" style="display:none;">
          <p><a id="book-repo" href="https://github.com/brettmrice/Clinical-Hematology">View book source <i class="fab fa-github"></i></a></p>
        </div>
      </nav>
</div>
  </header><main class="col-sm-12 col-md-9 col-lg-7" id="content"><div id="thrombin-inhibitors" class="section level1 unnumbered">
<h1>Thrombin Inhibitors<a class="anchor" aria-label="anchor" href="#thrombin-inhibitors"><i class="fas fa-link"></i></a>
</h1>
<div id="overview-of-direct-thrombin-inhibitors-dtis" class="section level2 unnumbered">
<h2>
<strong>Overview of Direct Thrombin Inhibitors (DTIs)</strong><a class="anchor" aria-label="anchor" href="#overview-of-direct-thrombin-inhibitors-dtis"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li><p><strong>Definition:</strong> Direct thrombin inhibitors (DTIs) are a class of anticoagulant medications that directly bind to and inhibit the activity of thrombin (Factor IIa), a key enzyme in the coagulation cascade</p></li>
<li>
<p><strong>Mechanism of Action:</strong> DTIs bind to thrombin and prevent it from:</p>
<ul>
<li>Cleaving fibrinogen to form fibrin</li>
<li>Activating other coagulation factors (e.g., Factors V, VIII, XI, XIII)</li>
<li>Activating platelets</li>
</ul>
</li>
<li>
<p><strong>Advantages over Warfarin:</strong></p>
<ul>
<li>Predictable anticoagulant response: DTIs have a more predictable anticoagulant effect than warfarin, reducing the need for routine monitoring in many patients</li>
<li>Rapid onset of action: DTIs have a rapid onset of action, allowing for immediate anticoagulation</li>
<li>Fewer drug and food interactions: DTIs have fewer interactions with other medications and foods compared to warfarin</li>
</ul>
</li>
<li>
<p><strong>Types of DTIs:</strong></p>
<ul>
<li>Univalent (Small Molecule) DTIs:
<ul>
<li>Bind to the active site of thrombin</li>
<li>Examples:
<ul>
<li>Dabigatran (oral)</li>
<li>Argatroban (IV)</li>
</ul>
</li>
<li>Bivalent DTIs:
<ul>
<li>Bind to both the active site and the exosite 1 of thrombin</li>
<li>Hirudin: naturally derived from leeches, not often used anymore</li>
<li>Bivalirudin (IV)</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
<div id="laboratory-monitoring-of-dtis" class="section level2 unnumbered">
<h2>
<strong>Laboratory Monitoring of DTIs</strong><a class="anchor" aria-label="anchor" href="#laboratory-monitoring-of-dtis"><i class="fas fa-link"></i></a>
</h2>
<p>While DTIs offer several advantages over warfarin, laboratory monitoring may be necessary in certain situations:</p>
<ul>
<li>
<strong>Situations Requiring Monitoring:</strong>
<ul>
<li>Patients with renal insufficiency</li>
<li>Patients with extremes of body weight</li>
<li>Patients at high risk for bleeding or thrombosis</li>
<li>Patients undergoing urgent surgery or invasive procedures</li>
<li>Suspected overdose</li>
<li>Patients with liver disease (for argatroban)</li>
</ul>
</li>
<li>
<strong>Tests Used for Monitoring DTIs:</strong>
<ul>
<li>Diluted Thrombin Time (dTT)</li>
<li>Ecarin Clotting Time (ECT)</li>
<li>Anti-IIa Assay (Chromogenic Assay)</li>
<li>aPTT (Activated Partial Thromboplastin Time): Less sensitive and specific, but may be used for argatroban monitoring</li>
</ul>
</li>
</ul>
</div>
<div id="dabigatran-pradaxa" class="section level2 unnumbered">
<h2>
<strong>Dabigatran (Pradaxa)</strong><a class="anchor" aria-label="anchor" href="#dabigatran-pradaxa"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li><p><strong>Mechanism of Action:</strong> A direct thrombin inhibitor that binds reversibly to both free and clot-bound thrombin, preventing it from cleaving fibrinogen to fibrin</p></li>
<li>
<p><strong>Laboratory Monitoring:</strong></p>
<ul>
<li>Diluted Thrombin Time (dTT): The preferred test for assessing dabigatran levels
<ul>
<li>Principle: Measures the prolongation of the thrombin time in a diluted plasma sample</li>
<li>Procedure:
<ul>
<li>Dilute the patient’s plasma with a specific buffer</li>
<li>Add a known concentration of thrombin to the diluted plasma</li>
<li>Measure the clotting time</li>
</ul>
</li>
<li>Interpretation: The clotting time is directly proportional to the dabigatran concentration</li>
</ul>
</li>
<li>Ecarin Clotting Time (ECT):
<ul>
<li>Another test for measuring dabigatran levels</li>
<li>More sensitive than dTT but less widely available</li>
</ul>
</li>
<li>Anti-IIa Assay (Chromogenic Assay):
<ul>
<li>A chromogenic assay that measures the inhibition of thrombin activity by dabigatran</li>
<li>More specific than dTT, but less commonly used for routine monitoring</li>
</ul>
</li>
<li>aPTT (Activated Partial Thromboplastin Time):
<ul>
<li>Prolonged by dabigatran, but not as sensitive or specific as dTT or ECT</li>
<li>Not recommended for routine monitoring</li>
</ul>
</li>
</ul>
</li>
<li>
<p><strong>Interpretation of Results:</strong></p>
<ul>
<li>Therapeutic Range: Varies depending on the clinical indication and the specific assay used
<ul>
<li>Refer to the laboratory’s established therapeutic range</li>
</ul>
</li>
<li>Elevated dTT, ECT, or Anti-IIa Activity: Indicates increased dabigatran levels
<ul>
<li>May increase the risk of bleeding</li>
</ul>
</li>
<li>Decreased dTT, ECT, or Anti-IIa Activity: Indicates decreased dabigatran levels
<ul>
<li>May increase the risk of thrombosis</li>
</ul>
</li>
</ul>
</li>
<li>
<p><strong>Idarucizumab (Praxbind):</strong></p>
<ul>
<li>A specific reversal agent for dabigatran</li>
<li>A monoclonal antibody that binds to dabigatran and neutralizes its anticoagulant activity</li>
<li>Used in emergency situations to reverse the effects of dabigatran (e.g., life-threatening bleeding, urgent surgery)</li>
</ul>
</li>
</ul>
</div>
<div id="argatroban" class="section level2 unnumbered">
<h2>
<strong>Argatroban</strong><a class="anchor" aria-label="anchor" href="#argatroban"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li><p><strong>Mechanism of Action:</strong> A direct thrombin inhibitor that binds reversibly to the active site of thrombin</p></li>
<li>
<p><strong>Laboratory Monitoring:</strong></p>
<ul>
<li>aPTT: The most commonly used test for monitoring argatroban therapy
<ul>
<li>The target aPTT range is typically 1.5-3 times the baseline aPTT</li>
</ul>
</li>
<li>Ecarin Clotting Time (ECT):
<ul>
<li>Can be used as an alternative to the aPTT</li>
<li>More sensitive to argatroban than the aPTT</li>
</ul>
</li>
<li>Anti-IIa Assay (Chromogenic Assay):
<ul>
<li>Measures the inhibition of thrombin activity by argatroban</li>
<li>Can be used to confirm argatroban levels in specific situations</li>
</ul>
</li>
</ul>
</li>
<li>
<p><strong>Interpretation of Results:</strong></p>
<ul>
<li>aPTT or ECT within the Therapeutic Range: Indicates adequate anticoagulation</li>
<li>Prolonged aPTT or ECT: Indicates excessive anticoagulation and increased risk of bleeding</li>
<li>Shortened aPTT or ECT: Indicates subtherapeutic anticoagulation and increased risk of thrombosis</li>
</ul>
</li>
<li>
<p><strong>No Specific Reversal Agent:</strong> There is no specific antidote to reverse the effects of argatroban</p>
<ul>
<li>Management of bleeding:
<ul>
<li>Discontinue argatroban</li>
<li>Administer procoagulant factors (e.g., prothrombin complex concentrate [PCC])</li>
<li>Consider hemodialysis (argatroban is dialyzable)</li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
<div id="bivalirudin" class="section level2 unnumbered">
<h2>
<strong>Bivalirudin</strong><a class="anchor" aria-label="anchor" href="#bivalirudin"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li><p><strong>Mechanism of Action:</strong> A direct thrombin inhibitor that binds to both the active site and the exosite 1 of thrombin</p></li>
<li>
<p><strong>Laboratory Monitoring:</strong></p>
<ul>
<li>aPTT: Can be used to monitor bivalirudin therapy, but the relationship between aPTT and bivalirudin concentration is variable</li>
<li>Ecarin Clotting Time (ECT):
<ul>
<li>More sensitive to bivalirudin than the aPTT</li>
<li>May be preferred for monitoring bivalirudin therapy</li>
</ul>
</li>
<li>Anti-IIa Assay (Chromogenic Assay):
<ul>
<li>Measures the inhibition of thrombin activity by bivalirudin</li>
<li>Can provide a more direct measurement of bivalirudin concentration</li>
</ul>
</li>
</ul>
</li>
<li>
<p><strong>Interpretation of Results:</strong></p>
<ul>
<li>aPTT or ECT within the Therapeutic Range: Indicates adequate anticoagulation</li>
<li>Prolonged aPTT or ECT: Indicates excessive anticoagulation and increased risk of bleeding</li>
<li>Shortened aPTT or ECT: Indicates subtherapeutic anticoagulation and increased risk of thrombosis</li>
</ul>
</li>
<li>
<p><strong>No Specific Reversal Agent:</strong> There is no specific antidote to reverse the effects of bivalirudin</p>
<ul>
<li>Management of bleeding:
<ul>
<li>Discontinue bivalirudin</li>
<li>Administer procoagulant factors (e.g., prothrombin complex concentrate [PCC])</li>
<li>Bivalirudin has a short half-life, so its effects will wear off relatively quickly</li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
<div id="general-considerations-for-dti-assays" class="section level2 unnumbered">
<h2>
<strong>General Considerations for DTI Assays</strong><a class="anchor" aria-label="anchor" href="#general-considerations-for-dti-assays"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<p><strong>Pre-Analytical Variables:</strong></p>
<ul>
<li>Improper Collection Technique: Tissue thromboplastin contamination or hemolysis</li>
<li>Correct Blood-to-Anticoagulant Ratio: Ensure that the collection tube is filled to the correct volume</li>
<li>Clotted Sample: Invalidates the results</li>
<li>Delayed Testing: Anticoagulant drugs can degrade over time</li>
<li>Improper Storage: Incorrect storage temperatures can affect results</li>
</ul>
</li>
<li>
<p><strong>Analytical Variables:</strong></p>
<ul>
<li>Instrument Malfunction: Ensure proper calibration and maintenance of the coagulation analyzer</li>
<li>Reagent Problems: Use fresh, properly stored reagents, and follow the manufacturer’s instructions</li>
<li>Interfering Substances: High levels of bilirubin, lipids, or paraproteins can interfere with optical clot detection</li>
</ul>
</li>
<li>
<p><strong>Patient-Related Variables:</strong></p>
<ul>
<li>Medications: Other medications that affect coagulation can influence DTI assay results</li>
<li>Liver Disease: Can affect the clearance of DTIs</li>
<li>Kidney Disease: Can affect the clearance of DTIs</li>
</ul>
</li>
</ul>
</div>
<div id="troubleshooting-erroneous-results-19" class="section level2 unnumbered">
<h2>
<strong>Troubleshooting Erroneous Results</strong><a class="anchor" aria-label="anchor" href="#troubleshooting-erroneous-results-19"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<p>If the DTI assay result is inconsistent with the patient’s clinical presentation:</p>
<ul>
<li>Check the sample for clots or hemolysis</li>
<li>Repeat the test on a fresh sample</li>
<li>Ensure that the correct blood-to-anticoagulant ratio was used</li>
<li>Verify the instrument and reagent quality control results</li>
<li>Investigate potential interfering substances</li>
<li>Review the patient’s medication list and medical history</li>
<li>Consult with a pathologist or coagulation expert</li>
</ul>
</li>
</ul>
</div>
<div id="key-terms-106" class="section level2 unnumbered">
<h2>
<strong>Key Terms</strong><a class="anchor" aria-label="anchor" href="#key-terms-106"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Direct Thrombin Inhibitor (DTI):</strong> An anticoagulant drug that directly inhibits thrombin (Factor IIa)</li>
<li>
<strong>Thrombin Time (TT):</strong> A test that measures the time it takes for a clot to form after the addition of thrombin</li>
<li>
<strong>aPTT (Activated Partial Thromboplastin Time):</strong> A test of the intrinsic and common pathways of coagulation</li>
<li>
<strong>Anti-IIa Assay:</strong> A chromogenic assay that measures the inhibition of thrombin activity</li>
<li>
<strong>Dabigatran:</strong> A direct thrombin inhibitor that is administered orally</li>
<li>
<strong>Argatroban:</strong> A direct thrombin inhibitor that is administered intravenously</li>
<li>
<strong>Bivalirudin:</strong> A direct thrombin inhibitor that is administered intravenously</li>
<li>
<strong>Idarucizumab:</strong> A specific reversal agent for dabigatran</li>
<li>
<strong>Ecarin Clotting Time (ECT):</strong> A coagulation test that is sensitive to direct thrombin inhibitors</li>
</ul>
</div>
</div>
<!-- Scoll to TOC element -->
<script>
  function scroll_to_element() {
    header_height = document.getElementsByTagName('header')[0].offsetHeight/2;
    toc_element_position = document.querySelector('.book-toc > li > a.active').offsetTop;
    document.getElementsByTagName('header')[0].scrollTo(0, toc_element_position - header_height, 'smooth');
  }
  window.onload = scroll_to_element();
</script><div class="chapter-nav">
<div class="prev"><a href="anti-xa.html">Anti-Xa</a></div>
<div class="next"><a href="heparin-neutralization.html">Heparin Neutralization</a></div>
</div></main><div class="col-md-3 col-lg-2 d-none d-md-block sidebar sidebar-chapter">
    <nav id="toc" data-toggle="toc" aria-label="On this page"><h2>On this page</h2>
      <ul class="nav navbar-nav">
<li><a class="nav-link" href="#thrombin-inhibitors">Thrombin Inhibitors</a></li>
<li><a class="nav-link" href="#overview-of-direct-thrombin-inhibitors-dtis">Overview of Direct Thrombin Inhibitors (DTIs)</a></li>
<li><a class="nav-link" href="#laboratory-monitoring-of-dtis">Laboratory Monitoring of DTIs</a></li>
<li><a class="nav-link" href="#dabigatran-pradaxa">Dabigatran (Pradaxa)</a></li>
<li><a class="nav-link" href="#argatroban">Argatroban</a></li>
<li><a class="nav-link" href="#bivalirudin">Bivalirudin</a></li>
<li><a class="nav-link" href="#general-considerations-for-dti-assays">General Considerations for DTI Assays</a></li>
<li><a class="nav-link" href="#troubleshooting-erroneous-results-19">Troubleshooting Erroneous Results</a></li>
<li><a class="nav-link" href="#key-terms-106">Key Terms</a></li>
</ul>

      <div class="book-extra">
        <ul class="list-unstyled">
<li><a id="book-source" href="https://github.com/brettmrice/Clinical-Hematology/blob/main/05-34-hemostasis-laboratory-hypercoagulability-dti.Rmd">View source <i class="fab fa-github"></i></a></li>
          <li><a id="book-edit" href="https://github.com/brettmrice/Clinical-Hematology/edit/main/05-34-hemostasis-laboratory-hypercoagulability-dti.Rmd">Edit this page <i class="fab fa-github"></i></a></li>
        </ul>
</div>
    </nav>
</div>

</div>
</div> <!-- .container -->

<footer class="bg-primary text-light mt-5"><div class="container"><div class="row">

  <div class="col-12 col-md-6 mt-3" style="text-align: center; flex: 100%; max-width: 100%;">
    <p>Written by Brett M. Rice | Updated 2025-02-23 | Built by the <a class="text-light" href="https://bookdown.org">bookdown</a> R package</p>
  </div>

  <!--div class="col-12 col-md-6 mt-3">
    <p>Built by the <a class="text-light" href="https://bookdown.org">bookdown</a> R package</p>
  </div-->

</div></div>
</footer>
</body>
</html>
